FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211103437> ?p ?o ?g. }

• W4211103437 endingPage "2862" @default.
• W4211103437 startingPage "2851" @default.
• W4211103437 abstract "Significance Statement Patients who survive coronavirus disease 2019 (COVID-19) are at higher risk of post-acute sequelae involving pulmonary and several extrapulmonary organ systems—generally referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available. Here we show that, beyond the acute phase of illness, 30-day survivors of COVID-19 exhibited higher risks of AKI, eGFR decline, ESKD, major adverse kidney events (MAKE), and steeper longitudinal decline in eGFR. The risks of kidney outcomes increased according to the severity of the acute infection (categorized by care setting into non-hospitalized, hospitalized, and admitted to intensive care). The findings provide insight into the long-term consequences of COVID-19 on kidney outcomes and suggest that post-acute COVID-19 care should include attention to kidney function and disease. Background COVID-19 is associated with increased risk of post-acute sequelae involving pulmonary and extrapulmonary organ systems—referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available. Methods We built a cohort of 1,726,683 US Veterans identified from March 1, 2020 to March 15, 2021, including 89,216 patients who were 30-day survivors of COVID-19 and 1,637,467 non-infected controls. We examined risks of AKI, eGFR decline, ESKD, and major adverse kidney events (MAKE). MAKE was defined as eGFR decline ≥50%, ESKD, or all-cause mortality. We used inverse probability–weighted survival regression, adjusting for predefined demographic and health characteristics, and algorithmically selected high-dimensional covariates, including diagnoses, medications, and laboratory tests. Linear mixed models characterized intra-individual eGFR trajectory. Results Beyond the acute illness, 30-day survivors of COVID-19 exhibited a higher risk of AKI (aHR, 1.94; 95% CI, 1.86 to 2.04), eGFR decline ≥30% (aHR, 1.25; 95% CI, 1.14 to 1.37), eGFR decline ≥40% (aHR, 1.44; 95% CI, 1.37 to 1.51), eGFR decline ≥50% (aHR, 1.62; 95% CI, 1.51 to 1.74), ESKD (aHR, 2.96; 95% CI, 2.49 to 3.51), and MAKE (aHR, 1.66; 95% CI, 1.58 to 1.74). Increase in risks of post-acute kidney outcomes was graded according to the severity of the acute infection (whether patients were non-hospitalized, hospitalized, or admitted to intensive care). Compared with non-infected controls, 30-day survivors of COVID-19 exhibited excess eGFR decline (95% CI) of −3.26 (−3.58 to −2.94), −5.20 (−6.24 to −4.16), and −7.69 (−8.27 to −7.12) ml/min per 1.73 m2 per year, respectively, in non-hospitalized, hospitalized, and those admitted to intensive care during the acute phase of COVID-19 infection. Conclusions Patients who survived COVID-19 exhibited increased risk of kidney outcomes in the post-acute phase of the disease. Post-acute COVID-19 care should include attention to kidney disease." @default.
• W4211103437 created "2022-02-13" @default.
• W4211103437 creator A5038406966 @default.
• W4211103437 creator A5044152940 @default.
• W4211103437 creator A5047490642 @default.
• W4211103437 creator A5088449459 @default.
• W4211103437 date "2021-11-01" @default.
• W4211103437 modified "2023-10-09" @default.
• W4211103437 title "Kidney Outcomes in Long COVID" @default.
• W4211103437 cites W1967862917 @default.
• W4211103437 cites W1993473555 @default.
• W4211103437 cites W2009428399 @default.
• W4211103437 cites W2033723052 @default.
• W4211103437 cites W2071273488 @default.
• W4211103437 cites W2114912107 @default.
• W4211103437 cites W2122861802 @default.
• W4211103437 cites W2126049444 @default.
• W4211103437 cites W2150408337 @default.
• W4211103437 cites W2514730604 @default.
• W4211103437 cites W2597503617 @default.
• W4211103437 cites W2601152064 @default.
• W4211103437 cites W2773395370 @default.
• W4211103437 cites W2810551427 @default.
• W4211103437 cites W2946854190 @default.
• W4211103437 cites W2980261817 @default.
• W4211103437 cites W2990638839 @default.
• W4211103437 cites W3017328206 @default.
• W4211103437 cites W3025040140 @default.
• W4211103437 cites W3035627211 @default.
• W4211103437 cites W3084212777 @default.
• W4211103437 cites W3087450863 @default.
• W4211103437 cites W3093025993 @default.
• W4211103437 cites W3104627571 @default.
• W4211103437 cites W3120562100 @default.
• W4211103437 cites W3153493739 @default.
• W4211103437 cites W3155987937 @default.
• W4211103437 cites W3157263169 @default.
• W4211103437 cites W3163666887 @default.
• W4211103437 cites W3177081741 @default.
• W4211103437 cites W4251381302 @default.
• W4211103437 doi "https://doi.org/10.1681/asn.2021060734" @default.
• W4211103437 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34470828" @default.
• W4211103437 hasPublicationYear "2021" @default.
• W4211103437 type Work @default.
• W4211103437 citedByCount "163" @default.
• W4211103437 countsByYear W42111034372021 @default.
• W4211103437 countsByYear W42111034372022 @default.
• W4211103437 countsByYear W42111034372023 @default.
• W4211103437 crossrefType "journal-article" @default.
• W4211103437 hasAuthorship W4211103437A5038406966 @default.
• W4211103437 hasAuthorship W4211103437A5044152940 @default.
• W4211103437 hasAuthorship W4211103437A5047490642 @default.
• W4211103437 hasAuthorship W4211103437A5088449459 @default.
• W4211103437 hasBestOaLocation W42111034372 @default.
• W4211103437 hasConcept C126322002 @default.
• W4211103437 hasConcept C159641895 @default.
• W4211103437 hasConcept C177713679 @default.
• W4211103437 hasConcept C201903717 @default.
• W4211103437 hasConcept C2778653478 @default.
• W4211103437 hasConcept C2779134260 @default.
• W4211103437 hasConcept C2780472472 @default.
• W4211103437 hasConcept C3008058167 @default.
• W4211103437 hasConcept C524204448 @default.
• W4211103437 hasConcept C71924100 @default.
• W4211103437 hasConcept C72563966 @default.
• W4211103437 hasConceptScore W4211103437C126322002 @default.
• W4211103437 hasConceptScore W4211103437C159641895 @default.
• W4211103437 hasConceptScore W4211103437C177713679 @default.
• W4211103437 hasConceptScore W4211103437C201903717 @default.
• W4211103437 hasConceptScore W4211103437C2778653478 @default.
• W4211103437 hasConceptScore W4211103437C2779134260 @default.
• W4211103437 hasConceptScore W4211103437C2780472472 @default.
• W4211103437 hasConceptScore W4211103437C3008058167 @default.
• W4211103437 hasConceptScore W4211103437C524204448 @default.
• W4211103437 hasConceptScore W4211103437C71924100 @default.
• W4211103437 hasConceptScore W4211103437C72563966 @default.
• W4211103437 hasFunder F4320306127 @default.
• W4211103437 hasFunder F4320306605 @default.
• W4211103437 hasIssue "11" @default.
• W4211103437 hasLocation W42111034371 @default.
• W4211103437 hasLocation W42111034372 @default.
• W4211103437 hasLocation W42111034373 @default.
• W4211103437 hasOpenAccess W4211103437 @default.
• W4211103437 hasPrimaryLocation W42111034371 @default.
• W4211103437 hasRelatedWork W2026519967 @default.
• W4211103437 hasRelatedWork W2114905932 @default.
• W4211103437 hasRelatedWork W2291230351 @default.
• W4211103437 hasRelatedWork W2341805355 @default.
• W4211103437 hasRelatedWork W2611563387 @default.
• W4211103437 hasRelatedWork W2883957337 @default.
• W4211103437 hasRelatedWork W2946401691 @default.
• W4211103437 hasRelatedWork W2974523597 @default.
• W4211103437 hasRelatedWork W2998743371 @default.
• W4211103437 hasRelatedWork W3005715211 @default.
• W4211103437 hasVolume "32" @default.
• W4211103437 isParatext "false" @default.
• W4211103437 isRetracted "false" @default.
• W4211103437 workType "article" @default.